Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelfinavir in Gammaherpesvirus-Related Tumors
NCT02080416Phase 1Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nelfinavir in non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), Kaposi sarcoma (KS) and 3 more, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Lytic activation of viral gene expression by NFV at Day 5. Started Jul 2014; status: terminated.
02
Drugs
nelfinavir
03
Conditions
non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)Kaposi sarcoma (KS)gastric cancer (GC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02080416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02080416.